CLAIMS

1. Use of a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in the manufacture of a medicament for treating or preventing headache in a subject, wherein:

i) the subject has been earlier treated with a first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody, which subject has a less than 5% reduction or is not responding as measured by reduction from baseline in Monthly Migraine Days ("MMD response") after said first dose, and

ii) wherein said medicament is to be administered to the subject as a second dose,

wherein said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in (i) and (ii) comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12.

2. Use of a therapeutically effective amount of a humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody in the manufacture of a medicament for treating or preventing headache in a subject, wherein:

i) the subject has been treated with a first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody and wherein it is to be determined whether said subject has a less than 5% reduction or is not responding as measured by reduction from baseline in Monthly Migraine Days ("MMD response") after said first dose, and

ii) wherein said medicament is to be administered as a second dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody, if the subject has been determined to have < 50% reduction from baseline in MMD response after said first dose,

wherein said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 6 and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 12.

3. The use **according to claims 1 or 2**, wherein the subject has migraine or cluster headache.

4. The use **according to claim 1, 2, or 3**, wherein said headache is episodic migraine, chronic migraine, episodic cluster headache or chronic cluster headache.

5. The use **according to claim 4**, wherein the subject experiences migraines with aura.

6. The use **according to claim 4** , wherein the subject experiences migraines without aura.

7. The use **according to any one of the preceding claims**, wherein the subject in step i) **of claim 1 or 2** has only received one dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody.

8. The use **according to any one of the preceding claims**, wherein said subject received the same dose in step i) and step ii) or a different dose in step i) and step ii).

9. The use **according to any one of the preceding claims,** wherein the monoclonal antibody is to be administered at a dose of 100 mg to 500 mg in step i) and a dose of 100 mg to 500 mg is to be administered in step ii) of claim 1 or 2.

10. The use **according to any one of the preceding claims**, wherein the monoclonal antibody is to be administered at a dose of about 100 mg, about 300 mg or about 400 mg in step i) and about 100 mg, about 300 mg or about 400 mg is to be administered in step ii) of claim 1 or 2.

11. The use **according to any one of the preceding claims**, wherein the monoclonal antibody is to be administered about once every 3 months.

12. The use according **to any one of the preceding claims**, wherein said selected subject did not experience any MMD reduction after their first dose of said humanized monoclonal anti-calcitonin gene-related peptide (CGRP) antagonist antibody.